Avoro Capital Advisors 13F: New $284M Stake in CYTK

Avoro Capital Establishes Cytokinetics Position

Avoro Capital Advisors, a fund known for its focused bets in the healthcare and biotechnology sectors, has initiated a major new stake in Cytokinetics, Incorporated (NASDAQ: CYTK). According to its latest Form 13F filing with the SEC, the fund acquired 3,333,333 shares of the biopharmaceutical company. The newly established position was valued at $283,966,646 at the end of the reporting period.

Avoro Capital has a history of making concentrated moves in the biotech space, sometimes completely exiting positions like Ultragenyx Pharmaceutical and PTC Therapeutics to rotate capital into fresh opportunities. This substantial purchase represents a major commitment to Cytokinetics and suggests the fund sees strong potential in the drug developer's pipeline. Because 13F filings are backward-looking documents, they show holdings as of the end of the filing period, meaning Avoro's actual holdings today could differ.

Cytokinetics Stock Performance

On Saturday, the stock closed at $85.19. The company's shares have shown impressive upward momentum, trading comfortably above their 50-day moving average of $76.41 and their 200-day moving average of $70.03. The stock is currently trading near the upper end of its 52-week range, which spans from a low of $47.22 to a high of $88.31. Cytokinetics has a market capitalization of $9.39 billion.

Recent Earnings and Financial Health

Cytokinetics reported revenue of $67.67 million for its most recent quarterly period, though it experienced a revenue decline of 57.1% compared to the prior year. The company is not currently profitable, posting an earnings per share loss of $7.22, meaning it does not have a meaningful price-to-earnings ratio. However, Cytokinetics maintains a highly liquid balance sheet to fund its clinical trials, sporting an exceptionally strong current ratio of 6.66 and a quick ratio of 6.56. Investors are looking forward to the next quarterly financial update, which is scheduled for November 5, 2026.

Analysts Set New Price Targets

Wall Street researchers have been highly supportive of the company's prospects. On October 16, 2026, William Blair initiated coverage on the stock with an Outperform rating. Earlier in the month, on October 8, 2026, RBC Capital maintained its Outperform rating and adjusted its price target to $113.00. HC Wainwright & Co. reiterated a Buy rating with a $140.00 target on August 31, 2026.

Other major institutions have also expressed confidence. Barclays maintained an Overweight rating on August 13, 2026, and set a price target of $110.00, while JP Morgan maintained an Overweight rating with a $103.00 price target on the same day. Truist Securities kept a Buy rating with a $112.00 target on August 10, 2026. Citizens also maintained a Market Outperform rating on August 7, 2026, with a $110.00 target. Overall, 20 analysts cover the stock, carrying a consensus recommendation of strong buy and an average price target of $109.90.

Muscle-Targeting Therapies

Cytokinetics is a biopharmaceutical firm dedicated to discovering and commercializing small-molecule drug candidates that target muscle function. Its primary focus is on developing treatments for devastating cardiovascular and neuromuscular diseases. Its pipeline includes MYQORZO and Aficamten, which target cardiac muscle proteins to help patients suffering from hypertrophic cardiomyopathy and heart failure.

What's Ahead for Cytokinetics, Incorporated

Investors will want to keep a close eye on the upcoming November 5, 2026, earnings release for updates on the commercial rollout of Cytokinetics' cardiac treatments. Regulatory milestones and clinical trial readouts for its late-stage pipeline will also likely serve as key catalysts. While Avoro Capital's large purchase is a positive signal, investors should monitor future regulatory filings to see if the fund continues to accumulate shares or begins to trim its exposure.